ClinicalTrialsFinder
RecruitingNot ApplicableNCT06011980

Life-2023-02 Esophagogastric Variceal Bleeding

Life-2023-02 Study on the Efficacy of Growth Inhibitors After Endoscopic Treatment of Acute Esophagogastric Variceal Bleeding

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

33 participants

Start Date

Aug 1, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Esophageal Variceal Hemorrhage

Summary

Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria2

  • acute esophagogastric bleeding with hepatic cirhosis;
  • stable status (no active bleeding)

Exclusion Criteria5

  • endoscopic test limitation;
  • previous acute esophagogastric bleeding treatment history;
  • ICU;
  • pregnant;
  • Immunity disabled;

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGrowth Inhibitor

growth inhibitors for 250-500μg/h, ivgtt. for 5 days

Locations(1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hanzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06011980